Cellectis to Present Gene Therapy Findings at European Society of Cell and Gene Therapy Congress.

Cellectis announced the presentation of findings at the European Society of Cell and Gene Therapy congress. The study highlights the potential of circular single-stranded DNA as a universal, efficient non-viral template for gene therapy and presents a comprehensive study of TALE base editors' off-targets in the nuclear genome. The presentation will take place on October 8, 2025, from 2:00 p.m. to 3:30 p.m. CET.

Cellectis, a leading clinical-stage biotechnology company, will present its latest research at the European Society of Cell and Gene Therapy (ESGCT) annual congress, held from October 7-10, 2025, in Sevilla, Spain. The company will showcase two significant studies: the potential of circular single-stranded DNA (CssDNA) as a universal, efficient non-viral template for gene therapy and a comprehensive analysis of TALE base editors' (TALEB) off-target effects in the nuclear genome.

On October 8, 2025, from 2:00 p.m. to 3:30 p.m. CET, Julien Valton, Ph.D., Vice President of Gene Therapy at Cellectis, will present a poster titled "Circularization of Single-Stranded DNA Donor Template Unleashes the Power of Non-Viral Gene Delivery for Long-Term HSCs editing" Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress^[1]. This study highlights the strong potential of CssDNA as a universal and efficient non-viral DNA template for gene therapy applications. The research was previously presented as an oral presentation at the Homology-Directed Repair: The Path Forward Workshop in Sevilla on October 6, 2025.

On October 9, 2025, from 2:00 p.m. to 3:30 p.m. CET, Maria Feola, Ph.D., Senior Scientist and Team Leader of Gene Editing at Cellectis, will present a poster titled "Comprehensive analysis of TALEB off-target editing" Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress^[1]. This study evaluates the safety of TALEB, a fusion of a transcription activator-like effector domain (TALE), split-DddA deaminase halves, and an uracil glycosylase inhibitor (UGI), which can directly edit double strand DNA. The research found no evidence of biases towards off-site C-to-T editing at sites flanked by CTCF binding sites, a key DNA-binding protein that regulates genome organization and gene expression at genome-wide levels.

These presentations underscore Cellectis' commitment to advancing gene therapy and its pioneering role in the development of life-saving cell and gene therapies. The company's allogeneic approach for CAR T immunotherapies and its platform to develop gene therapies in other therapeutic indications position it as a key player in the biotechnology sector.